Results 191 to 200 of about 1,461,609 (326)

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin, Noa G. Holtzman, Challice L. Bonifant   +2 more
wiley   +1 more source

T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies [PDF]

, 2017
Arber, Caroline, Bonifant, Challice Lee, Cooper, Laurence J. N., Gerken, Claudia, Gottschalk, Stephen, Iwahori, Kota, Kakarla, Sunitha, Rodriguez-Cruz, Tania, Song, Xiao-Tong, Szöőr, Árpád, Torres, David, Velasquez, Mireya Paulina   +11 more
core   +1 more source

Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies. [PDF]

Int J Mol Sci
Yang HM.
europepmc   +1 more source

Rejuvenation of tumour-specific T cells through bispecific antibodies targeting PD-L1 on dendritic cells

Nature Biomedical Engineering, 2021
Longchao Liu, Jiahui Chen, J. Bae, Huiyu Li, Zhichen Sun, Casey Moore, Eric J Hsu, Chuanhui Han, J. Qiao, yang-xin fu   +9 more
semanticscholar   +1 more source

Secondary central nervous system lymphoma (SCNSL) in mantle cell lymphoma (MCL): Characteristics and risk factors in a Danish nationwide population‐based study

British Journal of Haematology, EarlyView.
In a nationwide cohort study, 873 patients with mantle cell lymphoma (MCL) were followed for a median of 7 years. During follow‐up, 28 patients developed secondary central nervous system (CNS) lymphoma (SCNSL) with a 5‐year cumulative incidence of 2.8% (95% confidence interval [CI] 1.7–3.9).
Trine Trab, Torgerð Ranadóttir, Iman Chanchiri, Ahmed Ludvigsen Al‐Mashhadi, Emma Berggreen Dall, Stine Rasch, Mette Johansen, Laura Mors Haunstrup, Gabriella Cunsolo, Christian Bjørn Poulsen, Thomas Stauffer Larsen, Simon Husby, Peter Brown, Eliza A. Hawkes, Tarec C. El‐Galaly, Kirsten Grønbæk   +15 more
wiley   +1 more source

Prolonged chimeric antigen receptor‐T apheresis to infusion time is associated with inferior outcomes in diffuse large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Chimeric antigen receptor (CAR) T‐cell therapy is effective for relapsed/refractory (r/r) diffuse large B‐cell lymphoma (DLBCL). However, delays between apheresis and infusion frequently occur due to limited facility capacity and prolonged bridging therapy, and the clinical impact of such delays remains uncertain.
Suguru Morimoto, Tomoyasu Jo, Toshio Kitawaki, Takashi Sakamoto, Chisaki Mizumoto, Junya Kanda, Momoko Nishikori, Kouhei Yamashita, Miki Nagao, Akifumi Takaori‐Kondo, Yasuyuki Arai   +10 more
wiley   +1 more source

Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease

Cell Reports
Summary: Herpes simplex virus (HSV) causes lifelong infections, including oral and genital herpes. There is no vaccine, and current antivirals are only partially effective at reducing symptoms and transmission.
Chingwei V. Lee, Hector Viadiu, Apurva Kalamkar, David I. Bernstein, Andrew Pae, Xinchao Yu, Sylvia Wong, Fernando J. Bravo, Sheng Ding, Elbert Seto, Magdeleine Hung, Yu Yu, Weimei Xing, Giuseppe A. Papalia, Wei Kan, Brian Carr, Majlinda Thomas, Leah Tong, Priyanka Desai, Nadine Jarrousse, Alexandre Mercier, Meghan M. Holdorf, Simon P. Fletcher, Emma Abernathy   +23 more
doaj  

Hematopoietic progenitor kinase-1 inhibition improves the in vitro efficacy of bispecific antibodies in CLL. [PDF]

Blood Adv
Shorer Arbel Y, Yitzhak L, Katz BZ, Herishanu Y.   +3 more
europepmc   +1 more source

Bispecific nanobody® as a new pharmacological drug for the selective inhibition of Trypsin‐3

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Proteolytic balance is dysregulated in many diseases, with proteases playing critical roles in pathological pathways. A high level of Trypsin‐3 expression has been implicated as a significant mediator of tumour progression and metastasis, and this protease is associated with poor prognosis for patients in various cancers.
Melissa David, Anaïs Faihy, Corinne Rolland, Anissa Edir, Astrid Canivet, Laetitia Ligat, Mireille Sebbag, Nathalie Vergnolle, Aurélien Olichon, Céline Deraison   +9 more
wiley   +1 more source

Care Coordination for Mosunetuzumab Therapy in Patients With Follicular Lymphoma in Community Practices: Learnings From the MorningSun Study Investigators. [PDF]

Cancer Med
Graff T, Flinn I, Sharman JP, Liu S, Anz BM, Gandhi M, Ayed A, Zuniga R, Mansoor AH, Cassoli LM, Wu M, Jani P, Biondo JML, Lin T, Burke JM.   +14 more
europepmc   +1 more source